Parkman Healthcare Partners LLC Purchases New Shares in MBX Biosciences, Inc. (NYSE:MBX)

Parkman Healthcare Partners LLC purchased a new position in shares of MBX Biosciences, Inc. (NYSE:MBX - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 170,000 shares of the company's stock, valued at approximately $3,133,000. Parkman Healthcare Partners LLC owned about 0.51% of MBX Biosciences at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of MBX. Nuveen Asset Management LLC purchased a new position in MBX Biosciences during the fourth quarter worth about $267,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in MBX Biosciences during the fourth quarter worth about $117,000. Deutsche Bank AG purchased a new position in MBX Biosciences during the fourth quarter worth about $80,000. Driehaus Capital Management LLC raised its stake in MBX Biosciences by 61.2% during the fourth quarter. Driehaus Capital Management LLC now owns 1,581,760 shares of the company's stock worth $29,152,000 after purchasing an additional 600,438 shares during the period. Finally, Citadel Advisors LLC raised its stake in shares of MBX Biosciences by 62.5% in the 4th quarter. Citadel Advisors LLC now owns 220,330 shares of the company's stock valued at $4,061,000 after acquiring an additional 84,722 shares during the period.

Insider Buying and Selling

In other news, Director Carl L. Gordon acquired 143,170 shares of MBX Biosciences stock in a transaction that occurred on Tuesday, February 18th. The stock was purchased at an average price of $10.84 per share, for a total transaction of $1,551,962.80. Following the completion of the transaction, the director now directly owns 3,255,000 shares in the company, valued at approximately $35,284,200. This trade represents a 4.60% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Ora H. Pescovitz purchased 7,693 shares of MBX Biosciences stock in a transaction dated Tuesday, April 8th. The shares were bought at an average price of $5.89 per share, with a total value of $45,311.77. Following the completion of the transaction, the director now owns 24,329 shares in the company, valued at approximately $143,297.81. This trade represents a 46.24% increase in their position. The disclosure for this purchase can be found here. Insiders have purchased a total of 198,365 shares of company stock valued at $2,066,119 over the last quarter. 52.19% of the stock is currently owned by insiders.

MBX Biosciences Price Performance

NYSE MBX opened at $10.27 on Wednesday. MBX Biosciences, Inc. has a 52-week low of $4.81 and a 52-week high of $27.50. The business's 50-day moving average price is $8.50 and its 200 day moving average price is $13.40.

Analyst Ratings Changes

A number of research analysts have commented on MBX shares. Guggenheim restated a "buy" rating and set a $44.00 price target on shares of MBX Biosciences in a research note on Thursday, April 10th. Citizens Jmp assumed coverage on MBX Biosciences in a report on Thursday, April 10th. They issued an "outperform" rating and a $38.00 target price on the stock. Finally, JMP Securities started coverage on MBX Biosciences in a report on Thursday, April 10th. They issued a "market outperform" rating and a $38.00 target price on the stock. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $37.50.

MBX Biosciences Profile

MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.

Want to see what other hedge funds are holding MBX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MBX Biosciences, Inc. (NYSE:MBX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.